Neurotech

19 November 2020

Initiation of Clinical Product Formulation Studies

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") is pleased to announce the commencement of stage 1 clinical product formulation and development studies for entry into clinical trial in calendar Q1/2021.

HIGHLIGHTS

- **Neurotech commences preliminary work for human clinical trials**
- **Studies to focus on optimum delivery system and appropriate dosages**
- **Further in-vitro study results due end of November**

Following successful preliminary results of in vitro studies in human neuronal cell studies, the clinical product development program is now underway to optimise and develop the most suitable product for phase 1 clinical trial program. The final results of the extensive in vitro studies are expected by the end of November.

Working together with ACS Laboratories (Melbourne), RMIT University and The Victorian College of Pharmacy, the top DOLCE/NTI strain will be developed into a practical, easy to use, patient friendly delivery system. The studies will provide all the necessary requirements and documentation for the commencement of Phase 1 Clinical Program under the Special Access Scheme.

Studies will focus on DOLCE/NTI lead product:

- Delivery system
- Optimum dosage regime

Preliminary in vitro results demonstrated that the DOLCE/NTI full spectrum strains provide a potent “neuroprotective” effect and greater potency when compared to CBD alone.

DOLCE/NTI full spectrum strains demonstrated:

- Reduced inflammation within the brain cells.
- Ability to improve mitochondrial viability in the presence of external toxic “insult” (an external toxic substance - glutamate).
- Increased cell health and viability in the presence of external “insult”.
- Up to 30% more potency than CBD isolate alone in all tests.
- Increased number of mitochondrial cells without any toxic “insult”.
- No negative effects on cell health and maintain cell viability.
- Neuroprotective activity in the presence of “insult”.

All these studies are part of Neurotech’s research into the potential of cannabinoids for medicinal use in treating neurological disorders including autism, epilepsy and ADHD.

Neurotech International Ltd
ABN 73 610 205 402
Suite 5 CPC, 145 Stirling Highway
Nedlands, Western Australia 6009
www.neurotechinternational.com

“Our recently released interim results demonstrating the potent neuroprotective effects of our unique cannabis strains has enabled a successful capital raising for the planned commencement of Phase 1 clinical studies early next year,” said Brian Leedman, Chairman of Neurotech. “The initiation of stage 1 product and formulation studies are vital steps before we can enter clinical studies and are designed to provide clinicians with the best options in respect to dosage and delivery system”.

Authority

This announcement has been authorised for release by the Board of the Company.

Further Information

Brian Leedman
Chairman
bleedman@neurotechinternational.com
+61 (0)41 228 1780

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 (0)41 066 7844

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on facilitating the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit:

http://www.neurotechinternational.com.
http://www.mentetech.com.